Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2015

Commission File Number 001-36866

 

 

SUMMIT THERAPEUTICS PLC

(Translation of registrant’s name into English)

 

 

85b Park Drive

Milton Park, Abingdon

Oxfordshire OX14 4RY

United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F  x            FORM 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ¨

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES  ¨            NO   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

 

 

 

---

On June 5, 2015, Summit Therapeutics plc (the “Company”) issued a press release announcing that it would announce its financial results for its first quarter ended April 30, 2015 on Thursday, June 11, 2015. A copy of this press release is attached as Exhibit 99.1 and incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

 

 

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

						SUMMIT THERAPEUTICS PLC
				By:		/s/ Erik Ostrowski
						Erik Ostrowski
						Chief Financial Officer
Date: June 5, 2015

---

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Press Release dated June 5, 2015 relating to Notice of First Quarter Financial Results

Exhibit 99.1

 

Summit Therapeutics plc

(“Summit” or the “Company”)

SUMMIT THERAPEUTICS TO REPORT FIRST QUARTER 2015 FINANCIAL

RESULTS ON 11 JUNE 2015

Oxford, UK, 5 June 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2015 on Thursday, 11 June 2015.

- END -

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

 

Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski (US office)		Tel: [phone]         [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson		Tel: [phone]
N+1 Singer (Broker) Aubrey Powell / Jen Boorer		Tel: [phone]
MacDougall Biomedical Communications (US media contact) Michelle Avery		Tel: [phone] [e-mail]
Peckwater PR (Financial public relations, UK) Tarquin Edwards		Tel: [phone] [e-mail]